Comparison of the adverse renal effects of different types of NSAID based on COX inhibition in patients with headaches
-
Published:2020
Issue:1
Volume:66
Page:55-63
-
ISSN:1857-8969
-
Container-title:Macedonian Pharmaceutical Bulletin
-
language:en
-
Short-container-title:Maced. Pharm. Bull.
Author:
Yzeiri Havziu Drita1, Gjorgjeska Biljana2, Miftari Visar3, Alili Idrizi Edita1, Alija Gjylaj1, Haxhiu Arlinda1
Affiliation:
1. Faculty of Medical Sciences, State University of Tetovo, Street Ilinden bb 1200, 1220 Tetovo, Republic of North Macedonia 2. Faculty of Medical Sciences, State University Goce Delcev, Krste Misirkov, 2000 Shtip, Republic of North Macedonia 3. Clinic of Neurology, Clinical Hospital- November 29, 1220 Tetovo, Republic of North Macedonia
Abstract
Migraine is a common headache disorder that causes significant disabilities. Non-selective cyclooxygenase (COX) inhibitors (piroxicam, ketoprofen and ibuprofen) are most widely-prescribed NSAIDs treatment of headaches. Celecoxib is another NSAID therapy that has been approved in the last several years, with different mechanisms of action. The purpose of the study is to follow the renal function and comparisons of nephrotoxicity of different types of NSAID based on COX inhibition, in patients with cefalea-migraine that has been treated for a long period.
Besides conventional markers of renal function (serum/urine creatinine determined by Jaffe's methods of enzymatic assay for urea in serum), we used nephelometry by β2 microglobulin (β2M) and photoelectric colorimetry for microalbuminuria in urine, to monitor glomerular and tubular functioning. Any history of kidney diseases was exclusion criteria to enter the study.
The results show that the greatest deviations are observed in β2M in terms of its increase in all patients treated with piroxicam and ketoprofen, in 91.7% of the patients treated with ibuprofen, and in 50% of patients treated with celecoxib. The most frequent decrease was shown in creatinine values in urine, in 50% of the patients of piroxicam-treated group, 66.7% of the group treated with ketoprofen and ibuprofen, and 75% of the patients treated with celecoxib.
Following the levels of specific biomarkers in urine we can recommend constant monitoring of renal functions during usage of different groups of NSAIDs and be careful while using analgesic-anti-inflammatory drugs.
Keywords: adverse renal effects, non-steroidal anti-inflammatory drugs, migraine
Publisher
Macedonian Pharmaceutical Association
Reference41 articles.
1. Barasch, J., Cincinnati Children’s Hospital Medical Center and Columbia University of New York, 2005. Method for the early detection of renal injury. U.S. Patent Application 11/096, 113. Available at: https://patents.google.com/patent/US20100028919. 2. Clive, D.M., Stoff, J.S., 1984. Renal syndromes associated with nonsteroidal antiinflammatory drugs. New England Journal of Medicine 310(9), 563-572. Available at: https://doi.org/10.1056/NEJM198403013100905. 3. Davis, M.E., Berndt, W.O., 1994. Renal methods for tocicology. Principles and methods of toxicology, third ed. Raven Press Ltd, New York, pp. 871-894. 4. Derry, S., Rabbie, R., Moore, R.A., 2013. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews (4). Available at: https://www.cochrane.org/CD008783/SYMPT_diclofenac-or-without-antiemetic-acute-migraine-headaches-adults. 5. Ejaz, P., Bhojani, K., Joshi, V.R., 2004. NSAIDs and kidney. JAPI 52(632-640), 371. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15847359.
|
|